N-(4-piperazin-1-ylphenyl)-acetamide | 116290-77-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(4-piperazin-1-ylphenyl)-acetamide
• 英文别名: N-[4-(1-piperazinyl)phenyl]acetamide；N-[4-(Piperazinyl)phenyl]acetamide；N-(4-piperazin-1-ylphenyl)acetamide
• CAS: 116290-77-8
• 化学式: C₁₂H₁₇N₃O
• mdl: MFCD09883294
• 分子量: 219.286
• InChiKey: YSAGBPKXODMPLA-UHFFFAOYSA-N

物化性质

• 熔点：
  191-193 °C
• 沸点：
  469.0±30.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Chlor-1-(phenoxy)-2-butanol 、 N-(4-piperazin-1-ylphenyl)-acetamide 生成 1-Phenoxy-4-[4-(4-acetvlaminophenyl)-1-piperazinyl]-2-butanol
  参考文献：
  名称：

  1-aryloxy-4-[((4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy

  摘要：

  该公式是1-芳氧基-4-[(4-芳基)-1-哌嗪基]-2-丁醇，其中Ar从以下组合中选择##STR2##或2,3或4-吡啶基）; X和X'从氢，低烷基，低烷氧基，卤素，三氟甲基，硝基，乙酰氨基，苯基或##STR3##乙酰，氰基，氨基甲酰，羧基或低烷基羧酸酯中选择; Y，Y'，Y"从与X和X'相同的组合中选择，但排除了苯基和取代苯基; Z和Z'从氢，低烷基或低烷氧基中选择，以及其药学上可接受的盐，用于抑制或对抗动物和人类的过敏反应，与过敏性反应相关的过敏性敏感性。

  公开号：

  US04882330A1
• 作为产物：
  描述：

  4'-溴乙酰苯胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 lithium hexamethyldisilazane 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 65.0~70.0 ℃ 、1.0 MPa 条件下， 反应 28.0h， 生成 N-(4-piperazin-1-ylphenyl)-acetamide
  参考文献：
  名称：

  利用 Pd 催化的 CN 键形成反应简明合成 Vesnarinone 及其类似物

  摘要：

  这是以下文章的同行评审版本：见，YY；党, TT; 陈，AQ; Seayad，AM，使用 Pd 催化的 C-N 键形成反应简明合成 vesnarinone 及其类似物。European Journal of Organic Chemistry 2014, 2014, (33), p 7405–7412，最终版本已在 https://dx.doi.org/10.1002/ejoc.201403054 上发表。根据 Wiley 自我存档条款和条件，本文可用于非商业目的。

  DOI：

  10.1002/ejoc.201403054

文献信息

• Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
  申请人：——

  公开号：US20030229067A1

  公开（公告）日：2003-12-11

  The subject invention provides compounds having the structure: 1 wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(═O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(═O)NR 8 R 9 , —(CH 2 ) m C(═O)OR 10 , —(CH 2 ) k C(═O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

  该主题发明提供具有以下结构的化合物： 1 其中， R 1 是取代或未取代的烷基，其中取代基是羟基、二羟基、羧基、—C(═O)NR a R b 、—NR a R b 、—NR a C(═O)NR a R b 、—NR a C(═O)OR a 、—OC(═O)NR a R b 或—NHC(═O)R a ； R 2 是氢或取代或未取代的烷基，其中取代基是羟基、二羟基、羧基、—C(═O)NR a R b 、—NR a R b 、—NR a C(═O)NR a R b 、—NR a C(═O)OR a 、—OC(═O)NR a R b 或—NHC(═O)R a ，或 R 1 、R 2 和N共同形成取代哌嗪、取代氮杂环丙烷环或取代的—(CH 2 ) 2 OH或—CH 2 C(═O)OH的吡咯烷环； R 3 是取代或未取代的苯基或5-6成员杂芳环，其中取代基是卤素、羟基、氰基、(C 1 -C 15 )烷基、(C 1 -C 15 )烷氧基或—NR a R b ； R 4 是氢或取代或未取代的(C 1 -C 15 )烷基； R 5 是—(CH 2 ) m OR 6 、—CHNOR 7 、—C(═O)NR 8 R 9 、—(CH 2 ) m C(═O)OR 10 、—(CH 2) k C(═O)NR 11 R 12 ； 其中R 6 是取代或未取代的(C 1 -C 30 )烷基、(C 3 -C 10 )环烷基或芳基、杂芳基或4-8成员杂环环； R 7 是氢或取代或未取代的(C 1 -C 30 )烷基、(C 1 -C 30 )烷基芳基； R 8 和R 9 各自独立地是氢或取代或未取代的(C 1 -C 30 )烷基、(C 1 -C 30 )烷基芳基、(C 1 -C 30 )烷基氨基、(C 1 -C 30 )烷氧基或饱和或不饱和的、单环或双环的、碳环或杂环环，或 R 8 、N和R 9 共同形成取代或未取代的4-8成员杂环环； R 10 是氢或取代或未取代的(C 1 -C 30 )烷基、(C 3 -C 10 )环烷基或芳基、杂芳基或杂环环； R 11 、N和R 12 共同形成4-8成员杂环环； R a 和R b 各自独立地是氢或烷基； m为0、1、2或3；和 k为1、2或3， 或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，以及一种治疗与需要此类治疗的受试者相关的A 2b 腺苷受体相关疾病的方法，包括向受试者施用该发明化合物的治疗有效量。
• Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives
  申请人：A. H. Robins Company, Incorporated

  公开号：US05086055A1

  公开（公告）日：1992-02-04

  A method of treating allergic disorders and pharmaceutical compositions therefore are disclosed for a series of 5-[(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives of Formula I. These compounds are useful in inhibiting Type I allergic ##STR1## responses in a living animal and thus can be used to treat allergic phenomena such as asthma, rhinitis, atopic dermatitis, chronic hives, allergic conjunctivitis and the like.

  揭示了一种治疗过敏性疾病的方法和药物组合物，用于一系列Formula I的5-[(4-芳基-1-哌嗪基)烷基]-2-噁唑烷酮衍生物。这些化合物在抑制活体动物中的I型过敏##STR1##反应方面很有用，因此可用于治疗哮喘、鼻炎、特应性皮炎、慢性荨麻疹、过敏性结膜炎等过敏现象。
• 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and
  申请人：A. H. Robins Company, Inc.

  公开号：US04960776A1

  公开（公告）日：1990-10-02

  Novel 4-aryl-N-[2-(dialkylamino and heterocyclicamino)alkyl]-1-piperazinecarboxamides of the formula: ##STR1## wherein B is oxygen or sulfur; Ar is selected from ##STR2## or 2, 3 or 4-pyridyl; X is selected from hydrogen, halogen, loweralkyl, loweralkoxy, amino, dimethylamino, nitro, trifluoromethyl, cyano, acetyl, acetylamino, aminocarbonyl, carboxy or loweralkylcarboxylic acid ester; Y is selected from hydrogen, halogen, loweralkyl, loweralkoxy, nitro, trifluoromethyl, cyano, acetylamino, aminocarbonyl, carboxy or loweralkyl carboxylic acid ester; Z is selected from hydrogen, loweralkyl or loweralkoxy; Q is selected from ##STR3## m is 1 to 3 inclusive; n is zero or 1; p is zero to 3 inclusive; R.sup.1, R.sup.2 and R.sup.3 are loweralkyl and may be the same or different, or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom may be form a heterocyclic residue; and the pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in a method of combating allergic response associated with anaphylactic sensitivity in animals and humans.

  该专利描述了一种化合物的结构，用于对抗动物和人类中与过敏性休克敏感性相关的过敏反应的方法。
• Benzo-fused 5-membered heterocyclic compounds, their production and use
  申请人：Ohkawa Shigenori

  公开号：US20070149558A1

  公开（公告）日：2007-06-28

  A compound represented by the formula: (wherein, R 1 and R 2 are the same or different and each represents a hydrogen atom, hydrocarbon group or heterocyclic group, or R 1 and R 2 may form, together with the adjacent carbon atom, a 3-8 membered iso- or heterocyclic group, R 3 represents a cyclic group, a hydroxy group, a mercapto group that may have oxo, or an amino group, R 4 represents a hydrogen atom, a hydrocarbon group, a hydroxy group, a mercapto group which may have oxo, or an amino group, or R 2 and R 4 may link together to form a double bond, X represents a bond or a linear hydrocarbon group, W represents an oxygen atom or a sulfur atom, ring B represents a 5-8 membered nitrogen-containing heterocyclic group, ring C represents a benzene ring, and represents a single bond or a double bond), or a salt or a prodrug thereof that has excellent neurodegenerative inhibitory activity and brain penetrability, and is useful as an agent for preventing/treating neurodegenerative diseases.

  该化合物的化学式为：(其中，R1和R2相同或不同，每个代表氢原子，烃基或杂环基，或者R1和R2可以与相邻的碳原子一起形成3-8个成员的异构或杂环基，R3代表环状基团，羟基，硫醇基，可能具有氧化作用的氨基基团，或R4代表氢原子，烃基，羟基，可能具有氧化作用的硫醇基或氨基基团，或R2和R4可以连接形成双键，X代表键或线性烃基，W代表氧原子或硫原子，环B代表一个5-8成员的含氮杂环基，环C代表苯环，并且代表单键或双键），或其盐或前药，具有优异的神经退行性抑制活性和脑穿透性，可用作预防/治疗神经退行性疾病的药物。
• PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
  申请人：Castelhano Arlindo

  公开号：US20080261943A1

  公开（公告）日：2008-10-23

  The subject invention provides compounds having the structure: wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NH C(═O) R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(═O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(═O)NR 8 R 9 , —(CH 2 ) m C(═O)OR 10 , —(CH 2 ) k C(═O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

  本发明提供了具有以下结构的化合物：其中，R1是取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NH C（═O） Ra；R2是氢或取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NHC（═O）Ra，或R1，R2和N共同形成取代的哌嗪，取代的氮杂环丙烷环或取代的吡咯烷环，取代基为—（CH2）2OH或—CH2C（═O）OH；R3是取代或未取代的苯基或5-6成员的杂芳基环，其中取代基为卤素，羟基，氰基，（C1-C15）烷基，（C1-C15）烷氧基或—NRaRb；R4是氢或取代或未取代的（C1-C15）烷基；R5是—（CH2）mOR6，—CHNOR7，—C（═O）NR8R9，—（CH2）mC（═O）OR10，—（CH2）kC（═O）NR11R12；其中，R6是取代或未取代的（C1-C30）烷基，（C3-C10）环烷基或芳基，杂芳基或4-8成员的杂环；R7是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基；R8和R9各自独立地是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基，（C1-C30）烷基氨基，（C1-C30）烷氧基或饱和或不饱和的单环或双环，碳环或杂环，或R8，N和R9共同形成取代或未取代的4-8成员的杂环；R10是氢或取代或未取代的（C1-C30）烷基，（C3-C10）环烷基，芳基，杂芳基或杂环；R11，N和R12共同形成4-8成员的杂环；Ra和Rb各自独立地是氢或烷基；m为0，1，2或3；k为1，2或3，或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，以及一种用于治疗与A2b腺苷受体相关的疾病的方法，包括向需要这种治疗的受体中施用本发明化合物的治疗有效量。